Figure 2.

LukS^E-DR chimeras are active cytolysins with the exception of LukS^E-DR1+4. A–D, viability of primary human PMNs treated with LukE and LukS DR chimeras and indicated F subunits (n = 3–11 donors). LukS^E-DR1 indicates LukS-PV with the DR1 from LukE, etc. D indicates LukD, F indicates LukF-PV, and B indicates HlgB. Noncanonical toxin pairs are denoted as EB for LukE + HlgB, etc. The data are pooled from at least two independent experiments and represent means ± S.E. ****, p < 0.0001. D, two-way ANOVA with Sidak's correction, compared with WT LukSF-PV.